267 related articles for article (PubMed ID: 30975996)
21. De novo loss-of-function variants in STAG2 are associated with developmental delay, microcephaly, and congenital anomalies.
Mullegama SV; Klein SD; Mulatinho MV; Senaratne TN; Singh K; ; Nguyen DC; Gallant NM; Strom SP; Ghahremani S; Rao NP; Martinez-Agosto JA
Am J Med Genet A; 2017 May; 173(5):1319-1327. PubMed ID: 28296084
[TBL] [Abstract][Full Text] [Related]
22. Cohesin SA2 is a sequence-independent DNA-binding protein that recognizes DNA replication and repair intermediates.
Countryman P; Fan Y; Gorthi A; Pan H; Strickland E; Kaur P; Wang X; Lin J; Lei X; White C; You C; Wirth N; Tessmer I; Piehler J; Riehn R; Bishop AJR; Tao YJ; Wang H
J Biol Chem; 2018 Jan; 293(3):1054-1069. PubMed ID: 29175904
[TBL] [Abstract][Full Text] [Related]
23. Loss of Tumor Suppressor
Daniloski Z; Smith S
Cancer Res; 2017 Oct; 77(20):5530-5542. PubMed ID: 28819029
[TBL] [Abstract][Full Text] [Related]
24. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
25. Targeting the nucleotide salvage factor DNPH1 sensitizes
Fugger K; Bajrami I; Silva Dos Santos M; Young SJ; Kunzelmann S; Kelly G; Hewitt G; Patel H; Goldstone R; Carell T; Boulton SJ; MacRae J; Taylor IA; West SC
Science; 2021 Apr; 372(6538):156-165. PubMed ID: 33833118
[TBL] [Abstract][Full Text] [Related]
26. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
27. Synthetic Lethality between Cohesin and WNT Signaling Pathways in Diverse Cancer Contexts.
Pallotta MM; Di Nardo M; Musio A
Cells; 2024 Mar; 13(7):. PubMed ID: 38607047
[TBL] [Abstract][Full Text] [Related]
28. Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors.
Lappin KM; Barros EM; Jhujh SS; Irwin GW; McMillan H; Liberante FG; Latimer C; La Bonte MJ; Mills KI; Harkin DP; Stewart GS; Savage KI
Cancer Res; 2022 Mar; 82(5):819-830. PubMed ID: 35027467
[TBL] [Abstract][Full Text] [Related]
29. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Kon A; Shih LY; Minamino M; Sanada M; Shiraishi Y; Nagata Y; Yoshida K; Okuno Y; Bando M; Nakato R; Ishikawa S; Sato-Otsubo A; Nagae G; Nishimoto A; Haferlach C; Nowak D; Sato Y; Alpermann T; Nagasaki M; Shimamura T; Tanaka H; Chiba K; Yamamoto R; Yamaguchi T; Otsu M; Obara N; Sakata-Yanagimoto M; Nakamaki T; Ishiyama K; Nolte F; Hofmann WK; Miyawaki S; Chiba S; Mori H; Nakauchi H; Koeffler HP; Aburatani H; Haferlach T; Shirahige K; Miyano S; Ogawa S
Nat Genet; 2013 Oct; 45(10):1232-7. PubMed ID: 23955599
[TBL] [Abstract][Full Text] [Related]
30. The expanding phenotypes of cohesinopathies: one ring to rule them all!
Piché J; Van Vliet PP; Pucéat M; Andelfinger G
Cell Cycle; 2019 Nov; 18(21):2828-2848. PubMed ID: 31516082
[TBL] [Abstract][Full Text] [Related]
31. Replication fork stability confers chemoresistance in BRCA-deficient cells.
Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
[TBL] [Abstract][Full Text] [Related]
32. Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors.
Lee SB; Segura-Bayona S; Villamor-Payà M; Saredi G; Todd MAM; Attolini CS; Chang TY; Stracker TH; Groth A
Sci Adv; 2018 Aug; 4(8):eaat4985. PubMed ID: 30101194
[TBL] [Abstract][Full Text] [Related]
33. STAG2 loss-of-function affects short-range genomic contacts and modulates the basal-luminal transcriptional program of bladder cancer cells.
Richart L; Lapi E; Pancaldi V; Cuenca-Ardura M; Pau EC; Madrid-Mencía M; Neyret-Kahn H; Radvanyi F; Rodríguez JA; Cuartero Y; Serra F; Le Dily F; Valencia A; Marti-Renom MA; Real FX
Nucleic Acids Res; 2021 Nov; 49(19):11005-11021. PubMed ID: 34648034
[TBL] [Abstract][Full Text] [Related]
34. PARPi focus the spotlight on replication fork protection in cancer.
Schlacher K
Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
[TBL] [Abstract][Full Text] [Related]
35. Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy.
Baillie KE; Stirling PC
Trends Cancer; 2021 May; 7(5):430-446. PubMed ID: 33203609
[TBL] [Abstract][Full Text] [Related]
36. Mutational inactivation of STAG2 causes aneuploidy in human cancer.
Solomon DA; Kim T; Diaz-Martinez LA; Fair J; Elkahloun AG; Harris BT; Toretsky JA; Rosenberg SA; Shukla N; Ladanyi M; Samuels Y; James CD; Yu H; Kim JS; Waldman T
Science; 2011 Aug; 333(6045):1039-43. PubMed ID: 21852505
[TBL] [Abstract][Full Text] [Related]
37. Cohesin mutations in myeloid malignancies made simple.
Viny AD; Levine RL
Curr Opin Hematol; 2018 Mar; 25(2):61-66. PubMed ID: 29278534
[TBL] [Abstract][Full Text] [Related]
38. Sister chromatid cohesion is required for postreplicative double-strand break repair in Saccharomyces cerevisiae.
Sjögren C; Nasmyth K
Curr Biol; 2001 Jun; 11(12):991-5. PubMed ID: 11448778
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments.
Liao H; Ji F; Helleday T; Ying S
EMBO Rep; 2018 Sep; 19(9):. PubMed ID: 30108055
[TBL] [Abstract][Full Text] [Related]
40. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
Bhattacharjee S; Nandi S
IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
